Growth Metrics

Novartis Ag (NVS) Change in Receivables (2022 - 2026)

Novartis Ag's Change in Receivables history spans 5 years, with the latest figure at -$504.0 million for Q1 2026.

  • On a quarterly basis, Change in Receivables changed N/A to -$504.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$256.0 million, a N/A change, with the full-year FY2025 number at -$94.0 million, changed N/A from a year prior.
  • Change in Receivables hit -$504.0 million in Q1 2026 for Novartis Ag, down from -$94.0 million in the prior quarter.
  • Over the last five years, Change in Receivables for NVS hit a ceiling of $328.0 million in Q3 2024 and a floor of -$920.0 million in Q1 2024.
  • Historically, Change in Receivables has averaged -$283.8 million across 5 years, with a median of -$136.0 million in 2022.
  • Biggest five-year swings in Change in Receivables: surged 380.34% in 2024 and later crashed 158.02% in 2025.
  • Tracing NVS's Change in Receivables over 5 years: stood at -$825.0 million in 2022, then skyrocketed by 85.82% to -$117.0 million in 2023, then skyrocketed by 238.46% to $162.0 million in 2024, then crashed by 158.02% to -$94.0 million in 2025, then crashed by 436.17% to -$504.0 million in 2026.
  • Business Quant data shows Change in Receivables for NVS at -$504.0 million in Q1 2026, -$94.0 million in Q4 2025, and $180.0 million in Q3 2025.